Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable Colorectal Carcinoma

Trial Profile

A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable Colorectal Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CXD 101 (Primary) ; Nivolumab (Primary)
  • Indications Carcinoma; Colorectal cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms CAROSELL
  • Sponsors Celleron Therapeutics
  • Most Recent Events

    • 06 Aug 2019 According to a Celleron Therapeutics media release, the company will present data from this study at ESMO 2019.
    • 20 Jun 2019 Status changed from recruiting to active, no longer recruiting.
    • 17 Jun 2019 Interim results, presented in a Celleron Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top